Biogen Inc.

IDP.DE·XETRA·Healthcare
Compare
229.25+6.20 (+2.78%)today
As of Nov 5, 10:38 AM CET · May be delayed up to 15 min · EUR

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close223.05
Open226.40
Day range226.40229.25
52-week range132.40231.10
Off day high0.00%
Off 52-week high−0.80%
Volume500
Avg. volume (3M)96.00
Market cap33.89B
EPS (TTM)1.99
Forward P/E—
P/E ratio (TTM)115.20
Dividend yield—
Beta (5Y)0.09
Shares outstanding147.82M
Short interest—
Earnings dateOct 28, 2026
Analyst target—
Profit margin3.38%

Against its peers

Compare in full ›
IDP.DE AMGN BMY SNW.F NVS LLY
Market cap 33.89B 258.82B 131.21B 100.84B 311.59B 1.26T
P/E (TTM) 115.2 27.7 14.2 24.3 31.5 46.0
Forward P/E — 19.5 9.6 9.7 16.6 28.3
Price/book 2.0 18.0 5.6 1.4 8.4 31.4
Dividend yield — 2.11% 3.93% 5.11% 2.87% 0.49%
1-year change +65.90% +51.61% +37.66% −2.66% +30.35% +51.26%
Today +2.78% +3.73% +4.02% +0.89% +3.59% +0.61%

The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.

Latest news

All IDP.DE news ›
Longevity.Technology·Negative

Biogen’s tau drug diranersen gets a CTAD spotlight

Alzheimer’s research has spent decades on amyloid, the sticky protein that clumps between brain cells. Tau is the other suspect, and it gets less of the glory. Biogen plans to change that a little this month. The company will present new…

FinancialContent·Positive

Biogen (BIIB) Stock Is Up, What You Need To Know

Shares of biotech company Biogen (NASDAQ:BIIB) jumped 3.5% in the pre-market session after JPMorgan upgraded the stock to Overweight from Neutral with a $300 price target, raised from $210. As detailed by Investing.com, Schott observed in…

Longevity.Technology·Positive

Biogen to share long-term trial results for its Alzheimer’s drugs

Biogen will present new data across its Alzheimer’s disease portfolio at the 19th Clinical Trials on Alzheimer’s Disease conference, 16–19 November 2026, in Boston. Presentations will include expanded results from the Phase 2 CELIA study…

The Globe and Mail·Negative

Stifel Nicolaus Sticks to Their Buy Rating for Biogen (BIIB)

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Biogen yesterday and set a price target of $286.00. Matteis covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Contineum Therapeutics, Inc. Class A, and…

The Globe and Mail·Negative

Biogen (BIIB) Receives a Buy from Needham

In a report released today, Ami Fadia from Needham reiterated a Buy rating on Biogen, with a price target of $290.00. According to TipRanks, Fadia is a 5-star analyst with an average return of 30.0% and a 54.46% success rate. Fadia covers…

From the 4Search news index, newest first.

In the news

117mentions in 30 days
117with it in the headline
Positivesentiment

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 117 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance